Literature DB >> 23723443

A new era for Waldenstrom macroglobulinemia: MYD88 L265P.

Steven P Treon1, Zachary R Hunter.   

Abstract

In this issue of Blood, Poulain et al demonstrate the high prevalence of the MYD88 L265P somatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight into its biological relevance in the growth and survival of WM.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23723443     DOI： 10.1182/blood-2013-04-494849

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  23 in total

1.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

Review 2.  Developing precision medicine in a global world.

Authors:  Eric H Rubin; Jeffrey D Allen; Jan A Nowak; Susan E Bates
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

3.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

4.  Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.

Authors:  Chendi Zhan; Ruxi Qi; Guanghong Wei; Emine Guven-Maiorov; Ruth Nussinov; Buyong Ma
Journal:  Protein Eng Des Sel       Date:  2016-08-08       Impact factor: 1.650

5.  MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Authors:  Maria Luisa Guerrera; Nickolas Tsakmaklis; Lian Xu; Guang Yang; Maria Demos; Amanda Kofides; Gloria G Chan; Robert J Manning; Xia Liu; Jiaji G Chen; Manit Munshi; Christopher J Patterson; Jorge J Castillo; Toni Dubeau; Joshua Gustine; Ruben D Carrasco; Luca Arcaini; Marzia Varettoni; Mario Cazzola; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

Review 6.  MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.

Authors:  O Landgren; N Tageja
Journal:  Leukemia       Date:  2014-02-27       Impact factor: 11.528

7.  MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen P MacNamara; Nadine S Aguilera; Steven H Swerdlow; James R Cook
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

8.  Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Authors:  Michele Cea; Antonia Cagnetta; Chirag Acharya; Prakrati Acharya; Yu-Tzu Tai; Cao Yang; Davide Lovera; Debora Soncini; Maurizio Miglino; Giulio Fraternali-Orcioni; Luca Mastracci; Alessio Nencioni; Fabrizio Montecucco; Fiammetta Monacelli; Alberto Ballestrero; Teru Hideshima; Dharminder Chauhan; Marco Gobbi; Roberto M Lemoli; Nikhil Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-06-10       Impact factor: 12.531

Review 9.  Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.

Authors:  Joseph Cannova; Peter Breslin S J; Jiwang Zhang
Journal:  Front Med       Date:  2015-08-22       Impact factor: 4.592

10.  Lymphoplasmacytic non-Hodgkin lymphoma/Waldenström's macroglobulinemia with CD5+, CD23+, and CD10-.

Authors:  Guido D'Angelo; Anna Maria Hotz; Marta Monti
Journal:  Blood Res       Date:  2013-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.